AMLX
Amylyx Pharmaceuticals, Inc.
$17.77
-0.61 (-3.32%)
At close · Jul 10
Market Cap
$1.98B
Shares
111,186,317
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$144.74M
+52%
FY2025
Gross Margin
93.19%
-0.1pp
FY2024
Operating Margin
-360.22%
-370.4pp
FY2024
Diluted EPS
-$1.53
+65.5%
FY2025
Operating Cash Flow
-$123.34M
+26.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | $0 | $87.37M | $380.79M | $22.23M | $285K | |
| — | $0 | $5.95M | $25.44M | $2.99M | — | |
| — | $0 | $81.42M | $355.35M | $19.24M | — | |
| — | — | 93.19% | 93.32% | 86.54% | — | |
| $95.9M | $90.4M | $104.08M | $128.19M | $93.45M | $44.04M | |
| $63.37M | $62.89M | $114.33M | $188.36M | $127.13M | $38.93M | |
| — | $0 | $22.85M | — | — | — | |
| $159.27M | $153.29M | $402.1M | $341.98M | $223.57M | $82.97M | |
| -$159.27M | -$153.29M | -$314.73M | $38.8M | -$201.34M | -$82.69M | |
| — | — | -360.22% | 10.19% | -905.72% | -29013.33% | |
| $9.64M | $9.3M | $13.81M | $16.16M | $4.29M | $36K | |
| $9.2M | $8.6M | $12.6M | $15.5M | $3.74M | -$5.24M | |
| — | -$144.69M | -$302.14M | $54.3M | -$197.6M | -$87.93M | |
| — | $46K | -$393K | $5.03M | $774K | — | |
| -$150.11M | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M | |
| — | — | -345.36% | 12.94% | -892.38% | -30852.98% | |
| -$149.87M | -$144.24M | -$302.03M | $49.55M | -$198.47M | -$87.92M | |
| USD/shares | — | -$1.53 | -$4.43 | $0.73 | -$3.39 | -$13.35 |
| USD/shares | — | -$1.53 | -$4.43 | $0.70 | -$3.39 | -$13.35 |
| shares | — | 94.57M | 68.14M | 67.23M | 58.5M | 6.59M |
| shares | — | 94.57M | 68.14M | 69.99M | 58.5M | 6.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.09×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 33.82×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.88×